Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 6/20 | 0.55 |
| ▸ | AXL | P30530 | 3/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.51 |
| ▸ | ULK1 | O75385 | 1/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CCNC | P24863 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CCNH | P51946 | 1/20 | 0.46 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502620 | 1.00 | CDK8 (0.55) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| Hydrochloric Acid SCHEMBL28300266 | 0.98 | CDK8 (0.53) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL4294342 | 0.81 | PIK3CA (0.64) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL12127266 | 0.80 | RIPK1 (0.71) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL4831501 | 0.78 | CDK8 (0.81) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL23655689 | 0.77 | CDK8 (0.56) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL28863242 | 0.76 | CDK8 (0.52) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL857125 | 0.76 | CDK8 (0.69) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL1328372 | 0.76 | RIPK1 (0.49) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL12148007 | 0.75 | CDK8 (0.55) | CDK8AXLPIK3CAPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109134267-B | Synthetic method of aromatic amine compound | 北京大学 | 2020-11-17 | — | — | CN | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| US-8877769-B2 | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | JANSEEN PHARMACEUTICA NV (BG) | 2014-11-04 | — | — | US | claimed |
| US-20130245022-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (US) | 2013-09-19 | — | — | US | claimed |
| US-8461159-B2 | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | Jannsen Pharmaceutica BV (BE) | 2013-06-11 | — | — | US | claimed |
| WO-2010141809-A1 | ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | claimed |
| WO-2010068453-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-17 | — | — | WO | claimed |
| EP-4716529-A2 | COMPOUNDS THAT RE-ACTIVATE MUTANT P53 | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12528797-B2 | Heterocyclic compounds for medical treatment | C4 THERAPEUTICS, INC. | 2026-01-20 | — | — | US | disclosed |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-20 | — | — | US | disclosed |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-20 | — | — | US | disclosed |
| US-12453708-B2 | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2025-10-28 | — | — | US | disclosed |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | RAPPORT THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2008028617-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-13 | — | — | WO | disclosed |
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2007-05-17 | — | — | US | disclosed |
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2007-05-17 | — | — | US | disclosed |
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2007-05-17 | — | — | US | disclosed |
| EP-1704147-A1 | PYRROLO[2,3-b] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THEM | Pfizer Italia S.r.l. (IT) | 2006-09-27 | — | — | EP | disclosed |
| US-20050209269-A1 | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2005-09-22 | — | — | US | disclosed |
| WO-2005063747-A1 | PYRROLO[2,3-b] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THEM | PFIZER ITALIA S.R.L. (IT) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12453708-B2 | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases | KEAP1, GOT2, COL1A1 | CDK8 2656/4885AXL 4714/4885PIK3CA 4734/4885 |
| US-12528797-B2 | Heterocyclic compounds for medical treatment | CRBN, CUL2, ADRM1 | CDK8 953/4885AXL 3137/4885PIK3CA 3169/4885 |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK3, CLK2, CLK1 | CDK8 550/4885AXL 1441/4885PIK3CA 2273/4885 |
| US-20130245022-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, GPR119 | CDK8 802/4885AXL 1722/4885PIK3CA 1547/4885 |
| US-20050209269-A1 | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K6, MAP3K3, MAP3K1 | CDK8 236/4885AXL 697/4885PIK3CA 34/4885 |
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K6, MAP3K1 | CDK8 30/4885AXL 501/4885PIK3CA 100/4885 |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | CDK8 565/4885AXL 275/4885PIK3CA 1647/4885 |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, F2R, PF4 | CDK8 998/4885AXL 2452/4885PIK3CA 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.